Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02508662 · ClinicalTrials.gov registry record

Registry Study for Personalized Cancer Therapy

A clinical trial, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
5
Enrollment target

NCT02508662: Completed study, sponsored by M.D. Anderson Cancer Center.

NCT02508662 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02508662 has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
5 participants
Enrollment target

Study Summary

Objectives: Primary Objectives: To evaluate the anti-cancer activity of commercially available, targeted anti-cancer therapies used off-label for treatment in patients with advanced solid cancer with known genomic aberrations. Secondary Objectives: To determine outcomes of patients who were treated with matched targeted anti-cancer therapies based on known genomic aberrations. To obtain treatment related adverse events in patients with advanced solid tumor who were treated with off -label targeted therapies. To determine co-genomic aberrations that may contribute to treatment response or resistance mechanisms. To determine feasibility of detecting the genomic alterations in plasma, and the genomic evolution of circulating biomarkers.

Primary Outcome

Evaluation of tumor: the same imaging technique used during the initial evaluation or more sophisticated studies performed once after 2 cycles. Patients with measurable disease assessed by standard RECIST (Version 1.1).

Interventions

  • OTHER Review of Screening Tests and Molecular Test Results

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2015-07-21
Est. Completion 2020-07-10
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT02508662 record still lists

NCT02508662 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Review of Screening Tests and Molecular Test Results is the first listed.

NCT02508662 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02508662 about?

NCT02508662 is a clinical study titled "Registry Study for Personalized Cancer Therapy". Objectives: Primary Objectives: To evaluate the anti-cancer activity of commercially available, targeted anti-cancer therapies used off-label for treatment in patients with advanced solid cancer with known genomic aberrations. Secondary Objectives: To determine outcomes of patients who were trea...

What is the current status of trial NCT02508662?

This trial is currently completed. The enrollment target is 5 participants. The study started on 2015-07-21. Estimated completion is 2020-07-10.

What interventions are being tested in trial NCT02508662?

The interventions under investigation include: Review of Screening Tests and Molecular Test Results (OTHER).

Who is sponsoring clinical trial NCT02508662?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02508662, the US trial registry maintained by the National Library of Medicine. NCT02508662 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.